MedPath

Post-marketing hospital centralized monitoring of clinical safety of Shuganning injectio

Phase 4
Recruiting
Conditions
Adverse drug reactions
Registration Number
ITMCTR2100004833
Lead Sponsor
The First Affiliated Hospital of Henan University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.During the monitoring period, all inpatients receiving Shuganning injection were observed;
2.The same patient with different times of medication, the interval between two times of medication is less than 3 days (<= 3 days), which is regarded as one observation object. More than 3 days (> 3 days), according to the new observation object.

Exclusion Criteria

Inpatients who are unable to collect the information needed for this study.

Study & Design

Study Type
Observational study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ADR/ADE;
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath